May 8, 2024
StemRIM Inc.

StemRIM Announces Setting the Record Date for Extraordinary General Meeting of Shareholders Convening and Holding of Extraordinary General Meeting of Shareholders, and Reduction of Capital Stock (Capital Decrease)

Osaka, Japan, May 8, 2024 – StemRIM Inc. (TSE:4599, President and CEO: Masatsune Okajima; “StemRIM” or “Company”) announces that it has decided during today's Board of Directors meeting, to setting the record date for Extraordinary General Meeting of Shareholders convening and holding of Extraordinary General Meeting of Shareholders, and reduction of capital stock.

1. Record Date, etc. for the Extraordinary General Meeting of Shareholders

In order to confirm the shareholders who are entitled to exercise their voting rights at the Extraordinary General Meeting of Shareholders, the Company shall set the record date to May 31, 2024 (Friday), and the shareholders listed or recorded in the final shareholder register as of this date shall be those who are entitled to exercise their voting rights.

1.	Date of public notice	May 9, 2024 (Thursday)
2.	Record date	May 31, 2024 (Friday)
3.	Method of public notice	Electronic public notice (publication on the Company’s website) https://stemrim.com

2. Scheduled date and agenda items of the Extraordinary General Meeting of Shareholders

1.	Date	2 p.m., Wednesday, July 24, 2024
2.	Place	Icho-kaikan, Main Hall, 2-2, Yamadaoka, Suita-city, Osaka
3.	Agenda of the Meeting	Reduction of capital stock (capital decrease)

3. Reduction of Capital Stock

(1) Purpose of capital reduction

To ensure flexibility and agility in future capital policies and reduce tax burdens, we will decrease the amount of stated capital and transfer it to the capital reserve based on the provisions of Article 447, Paragraph 1 of the Companies Act. This proposal is a non-repayable, gratuitous capital reduction, which will not change the total number of issued shares but will reduce the stated capital. Therefore, this will not affect the number of shares owned by the shareholders. Moreover, this reduction in stated capital will not change the company's net asset value or the total number of issued shares, so the net asset value per share will also remain unchanged.

(2) Outline of capital reduction

①Amount by which the capital stock will be reduced

The Company will decrease its capital stock of 208,071,950 yen by 218,071,950 yen to 10,000,000 yen.

②Method to be applied for the capital reduction

The Company will implement a capital reduction without compensation, in which only the amount of the capital stock will be reduced without any refund or change in the number of outstanding shares and will transfer the reduction of 208,071,950 yen to other capital surplus in full.

(3) Schedule for the capital reduction (plan)

1.	Date of resolution by the Board of Directors	May 8, 2024
2.	Date of public notice for the statement of creditors' objections (plan)	June 28, 2024
3.	Date of resolution at the Extraordinary General Meeting of Shareholders (plan)	July 24, 2024
4.	Deadline for the statement of creditors' objections (plan)	July 28, 2024
5.	Effective date of the capital reduction (plan)	July 30, 2024

(4) Future outlook

The matter is a transfer of money between different account titles in the net assets section in the balance sheet and results in no change in the amount of the Company's net assets. Consequently, there is no impact on its business results. The matter is subject to the approval of the submitted agenda at an Extraordinary General Meeting of Shareholders to be held on July 24, 2024.

About StemRIM Inc.

StemRIM Inc. is a biotech venture which began at Osaka University with the goal of realizing a new type of medicine called "Regeneration-Inducing Medicine™". The overall aim is to achieve regenerative therapy effects equivalent to those of regenerative medicine, solely through drug administration, without using living cells or tissues. Living organisms have inherent self-organizing abilities to repair and regenerate tissues that have been damaged or lost due to injury or disease. This ability arises from the presence of stem cells in the body that exhibit pluripotency i.e., can differentiate into various types of tissues. When tissues are damaged, these cells, therefore, exhibit proliferative and differentiative capabilities, promoting functional tissue regeneration. "Regeneration-Inducing Medicine™" is aimed at maximizing the tissue repair and regeneration mechanisms already present in the body. With this aim, StemRIM is currently developing one of its most advanced regenerative medicine products. Specifically, this product is designed to release (mobilize) mesenchymal stem cells from the bone marrow into the peripheral circulation upon administration, thus increasing the number of stem cells circulating throughout the body and promoting their accumulation in damaged tissues. Here, these stem cells should accelerate tissue repair and regeneration.

Certain disease areas expected to benefit from "Regeneration-Inducing Medicine ™" include epidermolysis bullosa (EB), acute phase cerebral infarction, cardiomyopathy, osteoarthritis of the knees, chronic liver disease, myocardial infarction, pulmonary fibrosis, traumatic brain injury, spinal cord injury, atopic dermatitis, cerebrovascular disease, intractable skin ulcers, amyotrophic lateral sclerosis (ALS), ulcerative colitis, non-alcoholic steatohepatitis (NASH), systemic sclerosis, and any other areas where treatment with extrapulmonary mesenchymal stem cells is promising.

Inquiries:

StemRIM Inc.
Management & Administrator Dept.
E-Mail: stemrim-ir@stemrim.com
X: @StemRIM_Inc

For more information, please visit the StemRIM website (https://stemrim.com/english/)